Objectives: To explore the expression of Galectin-1 and -9 and clinicopathological features in endometrial carcinoma (EC). Methods: Normal endometrium (NE), atypical endometrial hyperplasia (AH), and endometrial cancer were collected, and immunohistochemistry was used to detect the expression of Galectin-1 and -9 in all specimens in the same condition. Results: The positive rate of Galectin-1 expression in NE, AH, and endometrial cancer was 30, 70, and 90.2%. The positive rate of Galectin-9 expression in them was 20, 75, and 78.4%, respectively. The expression of Galectin-1 and -9 in the EC and AH was significantly higher than that in the NE (p< 0.05). However, there was no significant difference between the EC and the AH (p > 0.05). The expression of Galectin-1 in endometrial adenocarcinoma was significantly different among tissues of different histological grades, pathological stages, degrees of myometrial infiltration, or lymph node metastasis (p > 0.05). The expression of Galectin-9 in endometrial adenocarcinoma was significantly different among different historical grades, pathological stages, degrees of myometrial infiltration, and lymph node metastasis (p < 0.05). The expression of Galectin-9 in tissues at an early stage, with the degree of myometrial infiltration <1/2, and without lymph node metastasis, was significantly stronger than in those in the late stage, with a degree of myometrial infiltration ≥1/2 and lymph node metastasis. Conclusion: Both Galectin-1 and -9 were associated with the occurrence of EC and its pathological behavior. High expression of Galectin-1 suggests a poor prognosis, whereas high expression of Galectin-9 was associated with early pathological changes. Galectin-1 and -9 can provide references for early screening and indicate the prognosis of endometrial lesions, which are of great significance for patients’ quality of life.

1.
Cousin JM, Cloninger MJ. The role of -galectin-1 in cancer progression, and synthetic multivalent systems for the study of galectin-1.
Int J Mol Sci
. 2016 Sep;17(9):pii:E1566.
2.
Alves PM, Godoy GP, Gomes DQ, Medeiros AM, de Souza LB, da Silveira EJ, et al. Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue.
Pathol Res Pract
. 2011 Apr;207(4):236–40.
3.
Espelt MV, Croci DO, Bacigalupo ML, Carabias P, Manzi M, Elola MT, et al. Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth.
Hepatology
. 2011 Jun;53(6):2097–106.
4.
Qian D, Lu Z, Xu Q, Wu P, Tian L, Zhao L, et al. Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis.
Cancer Lett
. 2017 Jul;397(397):43–51.
5.
Rabinovich GA, Toscano MA. Turning ‘sweet’ on immunity: galectin-glycan interactions in immune tolerance and inflammation.
Nat Rev Immunol
. 2009 May;9(5):338–52.
6.
Liu FT, Yang RY, Saegusa J, Chen HY, Hsu DK. Galectins in regulation of apoptosis.
Adv Exp Med Biol
. 2011;705:431–42.
7.
Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival.
Cell Mol Life Sci
. 2007 Jul;64(13):1679–700.
8.
Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?
Trends Immunol
. 2002 Jun;23(6):313–20.
9.
Noda Y, Kondo Y, Sakai M, Sato S, Kishino M. Galectin-1 is a useful marker for detecting neoplastic squamous cells in oral cytology smears.
Hum Pathol
. 2016 Jun;52:101–9.
10.
Schulz H, Schmoeckel E, Kuhn C, Hofmann S, Mayr D, Mahner S, et al. Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.
Int J Mol Sci
. 2017 Jun;18(6):E1230.
11.
Zhang P, Zhang P, Shi B, Zhou M, Jiang H, Zhang H, et al. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.
Cell Death Dis
. 2014 Jan;5(1):e991.
12.
Su YC, Davuluri GV, Chen CH, Shiau DC, Chen CC, Chen CL, et al. Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma.
PLoS One
. 2016 Feb;11(2):e0148408.
13.
van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, et al. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma.
Hum Pathol
. 1996 Nov;27(11):1185–91.
14.
Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS. Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin.
J Clin Invest
. 1997 May;99(10):2452–61.
15.
Türeci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin’s disease.
J Biol Chem
. 1997 Mar;272(10):6416–22.
16.
Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer.
Clin Cancer Res
. 2005 Apr;11(8):2962–8.
17.
Wang Y, Sun J, Ma C, Gao W, Song B, Xue H, et al. Reduced Expression of Galectin-9 Contributes to a Poor Outcome in Colon Cancer by Inhibiting NK Cell Chemotaxis Partially through the Rho/ROCK1 Signaling Pathway.
PLoS One
. 2016 Mar;11(3):e0152599.
18.
Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and -predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
Hepatology
. 2012 Oct;56(4):1342–51.
19.
Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, Takayanagi S, et al. TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression.
Cell Stem Cell
. 2015 Sep;17(3):341–52.
20.
Abdel-Mohsen M, Chavez L, Tandon R, Chew GM, Deng X, Danesh A, et al. Human galectin-9 is a potent mediator of HIV transcription and reactivation.
PLoS Pathog
. 2016 Jun;12(6):e1005677.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.